My understanding is that OvPlex is more accurate than the current standard being used, CA125. It wont misclassiffy as many patients. In other words, it is more reliable than CA125 - & especially in early stage ovarian cancer (OC). Also, I think that OvPlex can classify healthy vs benign OC vs malignant OC, where as CA125 is limited to healthy vs OC - but less accurately. The former would definetely be a better clinical tool, in my opinion.
I somehow dont think that it'll be a good thing hearing that one may not have OC, when they actually may have & conversely diagnosing a person with OC, when they havent. It's a tool used for better diagnosis & hence, a proper evaluation going forward.
I will contact HTX to confirm accordingly.
HTX Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held